Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche's Tecentriq-Avastin Combo Improves PFS In Kidney Cancer Too

Executive Summary

Top-line results from Roche's Phase III IMmotion151 study indicates the first-line use of a Tecentriq-Avastin combination has a significant effect on patients with advanced renal cancer who are PD-L1 expressers, but further details from the study will only become available in 2018.

Advertisement

Related Content

Roche: No Major M&A Needed To Offset Biosimilar Threat
Pharma Q4 Results Preview: Pfizer, Merck, Roche, Amgen, Novo, Lilly, AstraZeneca
Stock Scan Q4 2017 – Q3 Reporting Chops $70bn From Pharma
Exelixis CEO Eyes Expanded Indications For Cabozantinib
The Year's Clinical Trials In Review: Big Hits In 2017
ASH In Review: Roche Refreshes Hematology Portfolio With Robust New Drugs
Bristol's Strong SITC: IDO, 1L Kidney Cancer And New Mechanism Data Bode Well
Another Opdivo Disappointment For BMS, This Time In Kidney Cancer
Immuno-Oncology Outlook: Pfizer's Inlyta Fits Well In Combos For Kidney Cancer

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100029

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel